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The epithelial-mesenchymal transition (EMT) has
been associated with the acquisition of motility, inva-
siveness, and self-renewal traits. During both normal
development and tumor pathogenesis, this change in
cell phenotype is induced by contextual signals that
epithelial cells receive from their microenvironment.
The signals that are responsible for inducing an EMT
and maintaining the resulting cellular state have
been unclear. We describe three signaling pathways,
involving transforming growth factor (TGF)-b and
canonical and noncanonical Wnt signaling, that
collaborate to induce activation of the EMT program
and thereafter function in an autocrine fashion to
maintain the resulting mesenchymal state. Downre-
gulation of endogenously synthesized inhibitors of
autocrine signals in epithelial cells enables the induc-
tion of the EMT program. Conversely, disruption of
autocrine signaling by added inhibitors of these path-
ways inhibits migration and self-renewal in primary
mammary epithelial cells and reduces tumorigenicity
and metastasis by their transformed derivatives.
INTRODUCTION
The epithelial-mesenchymal transition (EMT) affects critical
steps of morphogenesis by interconverting epithelial cell types
into cells with mesenchymal attributes (Acloque et al., 2009;
Thiery et al., 2009). EMT programs activated in carcinoma cells
enable them to acquire cellular traits associated with high-grade
malignancy, including the ability to complete various steps of the
metastatic cascade (Brabletz et al., 2005; Singh and Settleman,
2010). In addition, certain epithelial cells that pass through an
EMT acquire the self-renewing trait associated with normal
tissue (SCs) and cancer stem cells (CSCs) (Mani et al., 2008;
Morel et al., 2008). However, the signaling mechanisms that926 Cell 145, 926–940, June 10, 2011 ª2011 Elsevier Inc.induce and then maintain this mesenchymal/SC state have
remained unclear.
Diverseextracellular signalshavebeenreported to induceEMTs
in various cell types (Thiery et al., 2009). In response, pleiotropi-
cally acting transcription factors (TFs), such as Twist, Snail, Slug,
ZEB1, andZEB2, are induced that orchestrate EMTprograms.We
wished to determine whether EMTs induced in human mammary
epithelial cells (MECs) by diverse stimuli are manifestations of
a common underlying cellular program. In order to characterize
mechanisms that induce and subsequentlymaintain EMT-associ-
ated properties in normal and neoplastic MECs, we speculated
that autocrine signaling might play a key role in maintaining the
mesenchymal/SC state and therefore focused on growth factors
and morphogens operating in the extracellular space.
Initially, we utilized a spontaneously arising mesenchymal
subpopulation (MSP) of cells isolated from immortalized human
MECs (HMLE) (Elenbaas et al., 2001). Unlike the parental, largely
epithelialHMLEcells,MSPcells residedstably inamesenchymal/
SC state. In this respect, MSP resembled HMLE cells induced to
pass through an EMT by overexpression of the Twist EMT-TF
(HTwist) (Yang et al., 2004). The MSP cells differed significantly
from the HTwist cells, since induction and subsequent mainte-
nanceof thesecells in themesenchymal/SCstate occurredspon-
taneously and was not provoked by an experimentally predeter-
mined set of signals. Analyses of MSP cells have allowed us to
define a set of extracellular signals that operate in a paracrine
manner to induce entrance of HMLE cells into the mesen-
chymal/SC state and subsequently function as autocrine factors
to maintain residence in this state. These signals also control
the interconversion of primary stem- and progenitor cell-contain-
ing, basal MECs to lineage-restricted, luminal MECs, indicating
that they operate in normal mammary gland homeostasis.
RESULTS
A Mesenchymal Subpopulation Isolated from
Immortalized Human Mammary Epithelial Cells
We isolated a MSP of cells that were floating in the medium of
monolayer cultures of experimentally immortalized HMLE cells,
similar to the derivation of cell populations described elsewhere
(Chaffer et al., 2011). When transferred to new culture dishes,
MSP cells reattached and could be propagated as adherent
cultures (Figure 1A and Figure S1A available online). In contrast
to the epithelial island-forming, parental HMLE cells, the MSP
consisted of front-to-back polarized, single cells (Figures 1A
and 1B). Similar to HTwist cells, MSP cells expressed several
mesenchymal markers and EMT-TFs (Figures 1B–1D and Fig-
ure S1B). MSP cells also displayed a CD44hi/CD24– cell-surface
marker profile (Figure 1E), suggesting that they form part of the
naturally occurring CD44hi/CD24– SC subpopulation within
HMLE cell cultures (Mani et al., 2008).
The mammosphere assay measures anchorage-independent
proliferation at clonal density in vitro and has been associated
with the presence of mammary epithelial progenitor and SC
populations (Dontu et al., 2003). We therefore used the mammo-
sphere-forming abilities of these various cell populations to
gauge their content of SCs. Relative to the parental HMLE cells,
fluorescence-activated cell sorting (FACS)-isolated CD44hi/
CD24– HMLE cells were 5-fold, the MSP cells 12-fold, and the
HTwist cells 18-fold enriched in mammosphere-forming cells
(Figure 1F).
To test for another functional hallmark of themesenchymal/SC
state, we conducted in vitro motility assays. HTwist cells were
most migratory (45-fold compared to bulk HMLE cells), followed
by MSP cells (30-fold) and FACS-purified CD44hi/CD24– cells
(12-fold) (Figure 1G). We noted that the majority epithelial popu-
lation of parental HMLE cells displayed a CD44-med/CD24+ cell-
surface marker profile. When isolated by magnetic-activated
cell sorting (MACS) or FACS, this population was depleted of
mammosphere-forming and migrating cells, suggesting the
latter were contained exclusively within the CD44hi/CD24– pop-
ulation (Figures 1F and 1G). Together, our observations indicated
that spontaneously arising MSP cells represent a CD44hi/CD24–
subpopulation enriched for motile, mammosphere-forming cells.
Comparative Profiling of the Autocrine
Signaling Context
We speculated that maintenance of the mesenchymal/SC state
might depend on the activation of autocrine signaling loops, as
has been suggested for TGF-b-induced EMT in RAS-trans-
formed mouse MECs (Oft et al., 1996). To test this notion, we
studied secreted proteins released into the culture medium of
MACS-purified HMLE24+ and HTwist cells using antibody arrays
and extended these findings to the above-described MSP cells
(Figures S1C–S1E and Table S1). Based on functional grouping,
secreted factors associated with passage through an EMT con-
tained predominantly proangiogenic factors and proteins acting
in the Wnt and TGF-b signaling pathways (Table S2). For our
initial studies, we focused on factors likely to function in an auto-
crine rather than paracrine manner on other cells within the
tissue microenvironment; accordingly, the work described
below emphasizes Wnt and TGF-b signaling.
We complemented the above analyses with microarray gene
expression profiling of HMLE24+ and three independently derived
MSPcell lines. Cluster analysis with a previously published ‘‘EMT
core signature’’ based on HMLE cells ectopically expressing
various EMT-TFs, including Twist (Taube et al., 2010), revealedsignificant overlap with the three MSP cell lines, whereas the
HMLE24+ cells clustered with the bulk HMLE cells (Tables S3
and S4).EMT-Associated Autocrine Signaling: Activation
of TGF-b and Restriction of BMP Signaling
We initially focused on TGF-b signaling. We noted increased
secretion of TGF-b1 protein by HTwist and MSP cells, relative
to HMLE24+ cells (Figure 2A), correlating with increased activity
(1.5- to 2-fold) of a Smad-reporter plasmid (SBE4-luc, Figure 2B)
and Smad2 phosphorylation (Figure 2C), all indicators of active
TGF-b signaling. We noted that MSP cells propagated in culture
medium depleted of all growth factors retained Smad2 phos-
phorylation, supporting an autocrine origin of TGF-b (Figure 2D).
Our attention was also drawn to possible modulation of TGF-b
by BMP signaling: mutual antagonism of TGF-b and BMP
signaling pathways at several levels has been described (Guo
and Wang, 2009), and BMP signaling is known to antagonize
the TGF-b-driven EMT occurring during renal fibrosis (Zeisberg
et al., 2003). In our own hands, secreted protein and gene
expression profiling revealed two secreted BMP antagonists,
Chordin-like 2 and Gremlin, to be significantly upregulated in
MSP and HTwist compared to HMLE cells; this was confirmed
by reverse transcriptase-polymerase chain reaction (RT-PCR)
(Figure 2E).
These observations led us to interrogate the expression status
of BMP ligands by RT-PCR: relative to their messenger RNA
(mRNA) expression in the parental HMLE cells, several BMP
ligands were strongly downregulated in both HTwist and MSP
cells (Figure S2A). This suggested that TGF-b signaling might
be enabled in the HTwist and MSP cells through downregulation
of BMPs and upregulation of two BMP antagonists. Conse-
quently, we tested whether TGF-b signaling could be modulated
by the presence of BMP antagonists. Indeed, we observed an
increase of Smad2 nuclear translocation in epithelial HMLE24+
cells stimulated with low doses of TGF-b in the presence
of recombinant Gremlin or Chordin-like 2, relative to TGF-b
introduced on its own. This effect was presumably achieved
through neutralization by Gremlin and Chordin-like 2 of endoge-
nously expressed BMP ligands (Figure 2F). Conversely, nuclear
translocation of Smad2 after stimulation with a high concentra-
tion of TGF-b, presumably high enough to overcome inhibitory
signals by endogenous BMP production, could be inhibited by
concomitant addition of recombinant BMP4 to the growth
medium (Figure 2F).
Together, these observations indicated that HTwist and MSP
cells exhibit an extracellular signaling environment that restricts
BMP signaling via (1) loss of BMP ligand production and (2) up-
regulation of the secreted Chordin-like 2 and Gremlin BMP
antagonists. Given the above-mentioned role of BMP as a
TGF-b antagonist, this suggested that cells that have passed
through an EMT are more responsive to extracellular TGF-b
ligand, including the ligand that they secrete. Indeed, when we
treated HMLE24+ in parallel with MSP cells with recombinant
TGF-b, we found that MSP cells were more responsive, as
gauged by a 3- to 5-fold greater nuclear translocation of Smad
2/3 and SBE4-luc reporter activity (Figure S2B).Cell 145, 926–940, June 10, 2011 ª2011 Elsevier Inc. 927
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Figure 1. A Mesenchymal Subpopulation Isolated from Immortalized Human Mammary Epithelial Cells
(A) Bright-phase microscopy: MACS-purified HMLE24+, HMLE overexpressing Twist (HTwist), and reattached MSP cells.
(B) Immunofluorescence: adherens junction protein E-cadherin and tight-junction protein ZO-1 in HMLE24+, HTwist, and MSP cells.
928 Cell 145, 926–940, June 10, 2011 ª2011 Elsevier Inc.
EMT-Associated Autocrine Signaling: Canonical
and Noncanonical Wnt Signaling
We wished to determine whether Wnt signaling pathways, iden-
tified above as being activated upon entrance into a mesen-
chymal state, collaborated with TGF-b signaling in MSP and
HTwist cells. First, we found that secretion of the canonical
Wnt signaling antagonist Dickkopf-1 (DKK1) (Kuhnert et al.,
2004) was downregulated in both HTwist and MSP cells (Fig-
ure 2G). Second, gene expression of the secreted frizzled-
related protein 1 (SFRP1), which sequesters both canonical
and noncanonical Wnt ligands in the extracellular space (Suzuki
et al., 2004), was downregulated in HTwist and undetectable in
MSP relative to HMLE24+ cells (Figure 2H). Of the multiple SFRPs
encoded in the genome, SFRP1 was the only one expressed at
significant levels in HMLE24+ relative to MSP cells (Figure S2C).
We also examined whether production of Wnt ligands was
changed upon passage through an EMT. RT-PCR analysis
revealed upregulation of noncanonical Wnt ligands 5a and 16
in HTwist and MSP cells (confirmed by immunoblotting for
Wnt5a, Figure 2L), whereas other Wnt ligands were expressed
at comparable levels (Wnt2, 2b, and 6) or downregulated
(Figure S2D).
We measured the activity of b-catenin-dependent canonical
Wnt signaling pathway using the TOPFlash b-catenin/TCF-LEF
reporter assay (Veeman et al., 2003). Doing so revealed a
5-fold higher TOP relative to FOP (control) activity in HTwist
and a 20-fold higher TOP/FOP activity in the MSP cells (Fig-
ure 2J). In contrast, b-catenin/TCF-LEF activity was undetect-
able in the HMLE24+ cells. In addition, mRNA levels of Axin2,
a conserved b-catenin/TCF-LEF target gene, were upregulated
15- and 30-fold in HTwist and MSP cells, relative to HMLE24+
cells (Figure 2I). Together, these observations indicated that
b-catenin-dependent, canonical Wnt signaling was active in
HTwist and MSP cells but not in the parental HMLE24+ cells.
Because no Wnt ligand was present in the medium, we
concluded that canonical Wnt signaling operated in an autocrine
manner. Importantly, the observed concomitant downregulation
of Wnt antagonists appeared to be a rate-limiting determinant of
b-catenin/TCF-LEF transcriptional activity, as suggested previ-
ously for certain breast and colon cancer cell lines (Bafico
et al., 2004; Suzuki et al., 2004). Thus, we found that addition
of either recombinant DKK1 or SFRP1 proteins resulted in
1.5- and 2-fold reduction of TOPFlash reporter activity in the
HTwist and MSP cells, respectively (Figure 2K).
We also analyzed the activity of noncanonical Wnt signaling
pathways in HTwist and MSP cells; as mentioned above,
production of the noncanonical Wnt5a ligand was strongly upre-
gulated in theMSP andHTwist cells (Figure 2L).Wnt5a binding to
noncanonical Frizzled receptors has been shown to activate(C) Immunofluorescence: mesenchymal intermediary filament vimentin and epith
and Twist.
(D) Immunoblot: E- and N-cadherin, EMT-TFs ZEB1, Snail, and Slug; loading co
(E) Flow cytometry: CD44-APC and CD24-PE cell-surface staining. Numbers ind
(F) Mammosphere assay: bright-phase microscopy images and quantification of
CD24– and CD44-med(ium)/CD24+ HMLE cells. n = 12.
(G) Migration assay: microscopy images and quantification. n = 3.
Data are presented as mean ± standard error of the mean (SEM). See also Figurprotein kinase C (PKC) isoforms (Dissanayake et al., 2007).
Indeed, we observed significant levels of activated PKCs in
HTwist and MSP cells, but not in the HMLE24+ cells (Figure 2L).
In addition, JNK signaling has been shown to be activated by
Wnt5a and to mediate breast cancer invasion (Pukrop et al.,
2006). We found elevated phosphorylation of JNK and its
downstream target, c-Jun, in HTwist and MSP relative to the
parental HMLE24+ cells (Figure 2L). These results suggested
that autocrine noncanonical Wnt signaling was active in HTwist
and MSP cells, acting via at least two downstream pathways
involving the PKC and JNK proteins.
Autocrine Signaling Controls Migration
and Mammosphere Formation
The above experiments indicated that autocrine canonical and
noncanonical Wnt as well as TGF-b signaling pathways were
active in MSP and HTwist cells. To address whether ongoing
autocrine signaling was instrumental in maintaining residence
in themesenchymal/SC state, we added back to cultured HTwist
and MSP cell cultures some of the secreted inhibitory factors
that we found to be downregulated relative to the parental
HMLE24+ cells and assessed effects on motility and mammo-
sphere-forming ability.
Addition of either recombinant DKK1 or SFRP1 to the culture
medium of HTwist and MSP cells inhibited migration in a dose-
dependent manner (Figures 3A and 3B). At the highest concen-
tration, recombinant DKK1 reduced migration 10-fold, and
SFRP1 20-fold (Figures 3A and 3B). BMP4 had a less potent
effect on migration, inducing a 2-fold reduction in HTwist and
MSP cells (Figure 3C). Of note, proliferation of adherent HTwist
and MSP cultures was not affected by these proteins, excluding
general cytostatic and cytotoxic effects (Figure S3A).
To test the effects of Wnt antagonists and BMP ligands on
mammosphere-forming ability, we added various proteins daily
for a period of 5d beginning from initial seeding of cells. We
then dissociated the initially formedmammospheres and reintro-
duced these cells into secondary mammosphere cultures in the
absence of further treatment. We observed a modest reduction
of sphere formation by DKK1 (Figures 3D and 3E). SFRP1 and
BMP4 had a more potent effect, reducing secondary sphere
formation by 80%–90% in MSP and HTwist cells (Figure 3E).
Taken together, these data indicated that SFRP1 and BMP4,
and to a lesser extent DKK1, inhibit migration and self-renewal.
We also tested the cooperative effects of these factors. Thus,
we added either DKK1 or SFRP1 in combination with BMP4
to HTwist cells: doing so inhibited migration in an additive
manner (8- and 7-fold, respectively, compared to 3-, 5-, and
2-fold when added individually, Figure 3F). During primary
mammosphere formation, we observed a 74% reduction inelial cytokeratins (panCK, pan-cytokeratin antibody), expression of fibronectin
ntrol, b-actin.
icate the percent of CD44hi/CD24– population.
parental HMLE, HMLE24+, HTwist, and MSP as well as FACS-purified CD44hi/
e S1.
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Figure 2. EMT-Associated Autocrine Signaling
(A) ELISA: TGF-b1 secretion by HMLE24+, HTwist, and MSP cells. n = 3.
(B) Luciferase reporter assay: Smad transcriptional activity. Cells were transfected with SBE4-luc reporter plasmid, and firefly luciferase levels were normalized to
pGL-SV40 renilla transfection control. n = 3.
(C) Immunoblot: Smad2 phosphorylation in HMLE24+, HTwist, and MSP cells. Loading control, b-actin.
(D) Immunoblot: Smad2 phosphorylation. Loading control, b-actin. Cells were cultivated 24 hr in full medium (++), growth factors reduced by 90% (+), or growth
factor free (–).
(E) RT-PCR: mRNA expression of BMP antagonists Gremlin and Chordin-like 2, both relative to HMLE24+ cells.
(F) Immunofluorescence: modulation of Smad2/3 nuclear translocation by BMP antagonists and ligand. HMLE24+ cells were stimulated with TGF-b1
(low, 0.3 ng/ml; high, 2.5 ng/ml) alone or together with Chordin-like 2, Gremlin (both 2.5 mg/ml), or BMP4 (0.5 mg/ml) for 30 min.
(G) RT-PCR: DKK1-mRNA expression. ELISA: DKK1-protein secretion. n = 3.
(H) RT-PCR: SFRP1-mRNA expression.
(I) RT-PCR: Axin2-mRNA expression.
(J) Luciferase reporter assay (TOPFlash): cells were transfected with Super(8x)TOP (TCF-LEF reporter) or FOP construct (mutated binding sites). Shown is TOP
over FOP firefly luciferase activity, normalized to pGL-SV40 renilla transfection control. n = 3.
(K) Inhibition of TOPFlash activity: DKK1 or SFRP1 protein (1.0 mg/ml) was added to the growth medium of HTwist and MSP for 12 hr. n = 3.
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Figure 3. Autocrine Signaling Controls
Migration and Mammosphere Formation
(A) Migration assay: DKK1 or SFRP1 protein
(0.5 mg/ml) was added to growth medium. #HMLE
control versus HTwist and MSP control, p < 1 3
106; *HTwist or MSP control versus treatment
with DKK1 or SFRP1, p < 1 3 106. n = 3.
(B) Migration assay: dose-dependent inhibition of
migration by DKK1 or SFRP1 protein at indicated
concentrations (mg/ml). *HTwist or MSP control
versus treatment with DKK1 or SFRP1, p < 1 3
106; ** HTwist or MSP, high versus low concen-
tration, p < 1 3 107. n = 3.
(C) Migration assay: dose-dependent inhibition of
migration by recombinant BMP4 protein at indi-
cated concentrations (mg/ml). *HTwist or MSP
control, p < 0.05; **0.6 mg/ml versus 1.2 mg/ml,
p < 1 3 104. n = 3.
(D) Mammosphere formation: DKK1, SFRP1 or
BMP4 protein was added daily during sphere
formation (5 days) at indicated concentrations
(mg/ml). *HTwist or MSP control versus treatment,
p < 0.01; **low versus high concentration or re-
combinant protein, p < 0.05. n = 8.
(E) Secondary mammosphere formation: DKK1
(1 mg/ml), SFRP1 (1 mg/ml), and BMP4 (0.5 mg/ml)
were added daily during primary sphere formation
(5 days), primary spheres were dispersed and
seeded for secondary sphere formation in the
absence of further treatment. *HTwist or MSP
control versus treatment, p < 0.01; **primary
versus secondary sphere number, p < 0.01. n = 16.
(F) Mammosphere assay: HTwist cells were
treated daily during mammosphere formation
(5 days) with proteins as described in (B). D+B,
DKK1 and BMP4 were added together; S+B,
SFRP1 and BMP4 were added together; *control
versus single treatment, p < 1 3 105; **single
versus double treatment, p < 0.01. n = 6.
(G) Migration assay: HTwist cells were seeded
into Boyden chambers in the presence of DKK1
(1 mg/ml), SFRP1 (1 mg/ml), BMP4 protein (0.5 mg/
ml), or in combination as indicated in (F). *Control
versus single treatment, p < 1 3 105; **single
versus double-treatment, p < 0.01. n = 3.
Data are presented as mean ± SEM. See also
Figure S3.sphere-forming efficiency when DKK1 or SFRP1 were added
together with BMP4 (Figure 3G). This compared to 40% reduc-
tion when either DKK1 or SFRP1 was added singly and a 64%
reduction when BMP4 was added singly.
These responses suggested that the three classes of secreted
signaling proteins work, at least in part, through distinct down-
stream pathways. To inhibit autocrine TGF-b signaling directly,(L) Immunoblot: PKC and JNK pathways associated with noncanonical Wnt sign
point to phosphorylated SAPK/JNK isoforms. Loading control, b-actin.
Data are presented as mean ± SEM. See also Figure S2.we used pharmacologic inhibitors of the TGF-b receptor
type I (TGFBRI); these attenuated migration and mammosphere
formation of HTwist and MSP cells to a similar extent as added
BMP4 protein (Figures S3D and S3E). However, the combination
of a TGFBRI inhibitor and BMP4 did not have an additive effect
(Figure S3D), suggesting that BMP4 exerts most of its inhibitory
effects by interfering with TGF-b signaling.aling. Phospho-JNK antibody generated an unspecific bottom band; asterisks
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Our findings emphasize the importance of ongoing autocrine
signaling in maintaining the mesenchymal/SC state of the MSP
cells. More surprising were the observed effects on HTwist
cells (Figures 3A–3E), suggesting that continuous expression
of the EMT-inducing Twist TF cannot maintain residence in
the mesenchymal/SC state through intracellular signaling, but
instead depends on extracellular autocrine signaling loops.
To further test this notion, we induced an EMT in HMLE cells
using a conditional Twist-ER expression vector (Casas et al.,
2011). We induced Twist expression for 12 days by application
of tamoxifen, after which these HTwist-ER cells maintained
a stable, mesenchymal/SC state in the absence of further
tamoxifen, presumably due to induced expression of endoge-
nous EMT-TFs (Figure S3F). Indeed, these cells remained
sensitive to inhibition of migration and mammosphere forma-
tion by SFRP1, BMP4, and a TGFBRI inhibitor (Figures S3G
and S3H).
Autocrine Signaling Controls Tumorigenicity
and Metastasis of MSP-RAS Cells
We also wished to determine whether autocrine loops maintain
the tumorigenic and metastatic behaviors of the RAS onco-
gene-transformed derivatives of HMLE cells. To begin, we
measured the tumor-initiating frequency of RAS-transformed
MSP and HMLE24+-cell populations. Similar to previously pub-
lished results (Mani et al., 2008), implantation of 1 3 105
HMLE24+-RAS cells was necessary for subcutaneous tumor
formation, whereas HTwist-RAS and MSP-RAS populations
were enriched for tumor-initiating cells by at least two orders
of magnitude (Figures S4A and S4B). Moreover, two indepen-
dently isolated MSP-RAS populations exhibited a 10-fold
increased ability to seed metastatic foci in the lung compared
to HMLE24+-RAS cells (Figures S4C–S4G).
Exposure in vitro of MSP-RAS cells to SFRP1 protein reduced
motility 9-fold, to BMP4 4-fold, and to a combination treatment
30-fold (Figure 4A). Importantly, proliferation of MSP-RAS cells
in monolayer culture was unaffected by the presence of these
recombinant proteins (Figure S4H).
As a surrogate assay for tumor-initiating ability, we tested the
formation of tumorspheres in three-dimensional cultures at
clonal densities (Fillmore and Kuperwasser, 2008). MSP-RAS
cells treated with recombinant SFRP1 and BMP4 during primary
tumorsphere formation displayed a reduction in both primary as
well as secondary sphere formation by 40% when each factor
was added alone, and by 60% when added in combination (Fig-
ure 4B). Together, these data indicated that autocrine signaling
continues to control migratory and self-renewal ability in MSP
cells after transformation by a RAS oncogene.
To determine whether in vitro exposure to SFRP1 and BMP4
influenced subsequent in vivo behavior of MSP-RAS cells,
we prepared single-cell suspensions from MSP-RAS tumor-
spheres and implanted them orthotopically in mice. We noted
that tumors originating from mammospheres of MSP-RAS cells
exposed ex vivo to SFRP1, BMP4, or a combination of both
were reduced in weight by 3-fold on average (Figure 4C and Fig-
ure S4J). We observed amodest reduction in tumor incidence for
the BMP4- and combination-treated groups (30%), suggesting
that sufficient numbers of tumor-initiating cells remained which932 Cell 145, 926–940, June 10, 2011 ª2011 Elsevier Inc.were, however, compromised in their ability to vigorously prolif-
erate and/or survive in vivo.
Further, we noted a 2-fold reduction in lung metastases in the
SFRP1-treated group, 7.5-fold in the BMP4-treated group, and
4.5-fold in the combination-treated group (Figure 4E). Echoing
the effects on migration in vitro, combination treatment with
SFRP1 and BMP4 had a synergistic effect in decreasing the
number of metastatic foci in the liver, by >10-fold on average,
compared to a 2.5- and 5-fold reduction in the mice bearing
cells treated ex vivo with SFRP1 or BMP4 singly (Figures 4F
and 4G).
We speculated that exposure to SFRP1 and BMP4 after
implantation in mouse hosts might exert a stronger effect on
the tumor-initiating ability of MSP-RAS cells. Accordingly, we
implanted these cells subcutaneously in limiting dilutions in
Matrigel plugs impregnatedwithSFRP1,BMP4, or a combination
of both (Figure 4G). In addition, recombinant proteins at indi-
cated doses were injected peritumorally 1, 2, 3, and 7 days after
implantation of the MSP-RAS cells. We found that exposure to
SFRP1, BMP4, or combination treatment reduced tumor inci-
dence by at least one order of magnitude (Figure 4H). Together,
these observations demonstrated that similar regulatory loops
were operative in the immortalized HMLE cells and their trans-
formed derivatives.
Creation of a Permissive Extracellular Environment
Promotes the Induction of an EMT in HMLE Cells
The above experiments revealed that ongoing autocrine
signaling through Wnt and TGF-b pathways was important for
maintaining the migratory and self-renewal abilities of cells that
resided in the mesenchymal/SC state. It remained possible
that these same pathways could activate an EMT program in
epithelial cells. To examine this, we treated HMLE24+ cells with
TGF-b, the first extracellular factor reported to induce an EMT
(Oft et al., 1996). However, treatment of HMLE24+ cells for
a period of 3 days with TGF-b, titrated to elicit maximal
Smad2-phosphorylation (Figure S5A), did not result in a change
in expression of mRNAs encoding epithelial and mesenchymal
markers, and EMT-TFs (Figure 5A). These data echoed previous
observations demonstrating that TGF-b on its own rarely induces
an EMT (Brown et al., 2004).
We therefore explored contributions of additional signaling
pathways to activation of the EMT program in HMLE24+ cells.
These involved modulation of Wnt signaling and destabilization
of adherens junctions. To reduce Wnt inhibition, we added
a DKK1-neutralizing antibody and knocked down expression
of the SFRP1-encoding mRNA (Figure S5B). We also added
recombinant Wnt5a, since Wnt5a was upregulated in HTwist
and MSP cells. To destabilize adherens junctions, we added
an anti-E-cadherin antibody; previous work suggested that
loss of E-cadherin is a rate-limiting step for EMT (Onder et al.,
2008).
To summarize our findings, only the presence of all of these
EMT-inducing components plus recombinant TGF-b1, which
together constituted the EMT induction cocktail (IC), led to
a significant induction of the mesenchymal marker N-cadherin
and the ZEB1 and ZEB2 EMT-TFs in HMLE24+ cells (Figure 5A
and Figures S5C and S5D).
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Figure 4. Autocrine Signaling Controls
Tumorigenicity and Metastasis
(A) Migration assay: SFRP1 (1 mg/ml) and BMP4
protein (0.5 mg/ml) were added to growth medium.
*Control versus single treatment, p < 1 3 108;
**single versus double treatment with SFRP1 and
BMP4 (S+B), p < 1 3 104. n = 3.
(B) Tumorsphere assay: SFRP1 (1 mg/ml) and
BMP4 protein (0.5 mg/ml) were added daily during
primary sphere formation (5 days), and spheres
were dissociated and seeded for secondary
sphere formation in the absence of further treat-
ment. #Control primary versus secondary sphere
formation, p = 0.001; *control versus single treat-
ment, p < 1 3 104; **single versus double treat-
ment with SFRP1 and BMP4 (S+B), p < 0.01. n = 6.
(C) Orthotopic tumor formation after ex vivo
treatment: primary tumorspheres as generated in
(B) were pooled and dissociated, and 1.0 3 105
cells were implanted in the mammary fat pads of
mice. Shown is tumor weight. * indicates the
absence of tumor. n = 5 mice/group.
(D) Lung metastasis: fluorescence microscopy
images with magnified insets of the major left lung
lobe showing GFP-positive metastatic foci.
(E) Quantification of lung surface metastatic foci.
*Control versus SFRP1 treatment, p < 0.05;
**SFRP1 versus BMP4 or double treatment (S+B),
p < 0.05. n = 5 mice/group.
(F) Liver metastasis: fluorescence microscopy
images and magnified insets of the liver surface
showing GFP-positive micrometastatic foci after
implantation of cells as described in (D).
(G) Quantification of liver surface metastastatic
foci. Five fields of liver surface were counted per
mouse. *Control versus single treatment, p < 0.05;
**single versus double treatment (S+B), p < 0.05.
n = 5 mice/group.
(H) Tumorigenicity assay: MSP-RAS cells sus-
pended in PBS containing SFRP1 (1 mg/ml), BMP4
(0.5 mg/ml), and a combination of both (S+B) were
implanted subcutaneously in mice at indicated cell
numbers. In addition, 20 ml PBS or PBS containing
recombinant protein was injected peritumorally at
1, 2, 3, and 7 days after implantation.
Data are presented as mean ± SEM. See also
Figure S4.Creation of a Permissive Extracellular Environment
for Stable Expression of Mesenchymal/SC Traits
To investigate whether the initiation of an EMT triggered by the IC
would yield cells that entered stably into the mesenchymal/SC
state, we treated HMLE24+ cells with TGF-b alone or with the
above-described IC (Figure 5A). Over 14 days, IC-treated cells
acquired a mesenchymal morphology, while control and TGF-
b-treated cells remained epithelial (Figures S5E and S5F). During
12 subsequent passages (36 population doublings) after
cessation of treatment, IC-treated cells remained mesenchymal
and did not revert back to an epithelial morphology.
In such phenotypically stable IC-treated cells, but not in those
treated only with TGF-b, we observed a switch from E- to N-cad-
herin expression and an upregulation of the Vimentin and Fibro-
nectin mesenchymal markers (Figure 5B and Figures S5G and
S5I). RT-PCR analysis of ZEB1, ZEB2, and Twist EMT-TFsprovided further evidence that IC-treated cells had moved
stably into a mesenchymal state: these mRNAs were upregu-
lated >100-fold compared to control cells and those treated
with TGF-b alone (Figure S5G).
On the basis of the work presented above, we speculated that
autocrine signaling loops involving the same factors that had
previously triggered entrance into an EMT were established in
these IC-treated cells. Indeed, relative to control and TGF-
b-treated cells, we observed a 3- to 4-fold increase in Smad-
reporter activity (Figure S5H) and Smad2 phosphorylation (Fig-
ure S5I). In IC-treated cells, we detected cytoplasmic and
nuclear b-catenin (Figure 5B) and b-catenin/TCF-LEF reporter
activity, indicative of canonical Wnt signaling (Figure S5H). We
also measured increased levels of Wnt5a and elevated phos-
phorylation of PKCs and JNK, indicative of noncanonical Wnt
signaling (Figure S5I).Cell 145, 926–940, June 10, 2011 ª2011 Elsevier Inc. 933
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Figure 5. Creation of a Permissive Extracel-
lular Environment for EMT Induction
(A) RT-PCR: mRNA expression of N-cadherin,
ZEB1, and ZEB2, all relative to untreated
control cells (HMLE24+-shGFP). HMLE24+-shGFP
or -shSFRP1 (short hairpin RNA-mediated knock-
down of SFRP1, Figure S5B) were treated for
3 days daily: anti-DKK1 antibody (aDKK1, 10 mg/
ml), anti-E-cadherin antibody (aEC, 1.0 mg/ml),
TGF-b1 (2.5 ng/ml), and Wnt5a (250 ng/ml). All
factors added together to HMLE24+-shSFRP1
constitutes the IC.
(B) Immunofluorescence: E-cadherin, b-catenin,
vimentin, and fibronectin expression in control
(HMLE24+-shGFP and HMLE24+-shSFRP1), TGF-
b-treated HMLE24+-shGFP, and IC-treated
HMLE24+-shSFRP1 cells (14 days of treatment).
(C and D) Mammosphere (C; n = 7) and migration
(D; n = 3) assays: cells were generated as indi-
cated in (B): a and b indicate independently
treated replicates. *Control versus TGFb treat-
ment, p < 1 3 104; **control versus IC treatment,
p < 1 3 109.
(E and F) Mammosphere (E; n = 6) and migration
(F; n = 3) assays: cells were expanded for 12
passages after cessation of treatment as
described in (B) and were then seeded into assays
in presence of SFRP1 (1 mg/ml/day), BMP4
(0.5 mg/ml/day) or both (S+B) proteins. *Control
versus single treatment, p < 0.01; **single versus
double treatment (S+B), p < 0.05.
(G) Flow cytometry: CD44-APC and CD24-PE
cell-surface staining in control-, TGF-b-, and IC-
treated cells generated as described in (B).
Numbers indicate percentage of CD44hi/CD24–
population.
(H) Lung metastasis: cells expanded for eight
passages after cessation of treatment as
described in (B) were transformed with RAS. Cells
were injected into the mammary fat pads of mice.
GFP-labeled metastases on the surface of the
lungs were quantified. *Control versus all other
groups, p < 0.05. n = 5 mice/group.
Data are presented as mean ± SEM. See also
Figure S5.Relative to control cells, IC-treated cells formed 70 timesmore
mammospheres, and their ability to migrate increased 50-fold
(Figures 5C and 5D). In contrast, cells treated only with TGF-b
displayed a small increase in mammosphere-forming efficiency
(10-fold) but not in motility. Echoing these results, we observed
a comparably small increase in the proportion of CD44hi/CD24–
cells in TGF-b-treated cells (from 0.2% to 1.5%) compared to
the 98% representation of CD44hi/CD24- cells in IC-treated
cultures (Figure 5F).
Importantly, these effects could not be attributed to increased
proliferation of the IC- and TGF-b-treated cells; their prolifera-
tion rates were lower than those of control cells (Figure S5F).
Moreover IC-treated cells remained sensitive to perturbation934 Cell 145, 926–940, June 10, 2011 ª2011 Elsevier Inc.of their autocrine environment: treatment of these cells with
SFRP1, BMP4 or a combination of both inhibited migration
and mammosphere formation (Figures 5E and 5F). Finally,
when these various cell populations were transformed with
a RAS oncogene, IC-treated cells, implanted into the mammary
fat pads of mice, gave rise to lung metastatic foci with a similar
elevated frequency as MSP-RAS cells. By contrast, control and
TGF-b-treated cells were only weakly metastatic (Figures 7G
and 7H).
Together, these various findings indicated that the same
factors involved in maintaining the mesenchymal/SC state can
also serve to induce entrance into this state, allowing the deriva-
tion of cells with stable migratory and SC properties from
populations that previously displayed these functional attributes
at very low levels.
Characterization of Primary Mammary Epithelial Cell
Populations Enriched in Self-renewal and Motility
We set out to explore whether the autocrine loops that govern
migratory and self-renewal traits in HMLE cells and their trans-
formed derivatives were also operative in cell populations
residing within the human mammary gland. In fact, stem and
progenitor cells had been previously resolved within CD49f+/
EpCAM– MEC populations (Eirew et al., 2008). Accordingly, we
prepared CD49f+ MEC populations from reduction mammoplas-
ties that were either positive or negative for expression of
EpCAM by FACS (MECEPC+ or MECEPC–, Figure S6A) and con-
ducted mammosphere assays to test for the presence of stem
and progenitor cells. We found that unsorted MECs displayed
a mammosphere-forming frequency of 0.15%–0.5%, compa-
rable to previous reports (Dontu et al., 2003). In contrast,
1%–2% of MECEPC– cells formed mammospheres, relative to
0.1%–0.3% of MECEPC+ cells (Figure 6A).
We noted that MECEPC+ cells formed epithelial islands,
whereas MECEPC– cells displayed a scattered mesenchymal
morphology (Figure S6B). Both MECEPC– and MECEPC+ cells ex-
pressed cytokeratins at similar levels; however, the MECEPC–
cells additionally expressed high levels of the mesenchymal
marker vimentin (Figure 6C). Despite similar levels of E-cadherin
mRNA (Figure S6C), MECEPC– cells did not form adherens or
tight junctions (Figure 6C). We next assessed the expression of
EMT-TFs and observed high expression levels of Slug, Twist,
ZEB1, and ZEB2 in MECEPC– but not MECEPC+ cells (Figure 6D
and Figure S6D). These data indicated that mesenchymal
properties were displayed specifically by populations of cells
enriched for self-renewal, similar to the phenotypes of the MSP
and HTwist cells studied previously.
In light of their mesenchymal morphology, we assessed
whether MECEPC– cells displayed increased motility. Indeed,
MECEPC– cells had a 20-fold greater ability to migrate in vitro
relative to unsorted bulk MECs and 40-fold relative to MECEPC+
cells (Figure 6B). Further, we found a 2-fold enrichment in mam-
mosphere formation in migrated MECEPC– cells collected from
the bottom of migration chambers compared to monolayer-
grown MECEPC– cells, suggesting a link between motility and
mammosphere-forming ability (Figure S6E).
To align these primaryMECpopulationswith knownmammary
gland lineages, we assessed the expression of lineagemarkers in
MECEPC+ cells and in MECEPC– cells. These analyses showed
enrichment in the expression of basal markers in MECEPC– cells
(p63, cytokeratin 14, a-smooth muscle actin) and of luminal
markers in MECEPC+ cells (Mucin-1, cytokeratin 8, 18) (Fig-
ure S6F). We concluded that MECEPC– cells represented popula-
tions of the basal lineage showing a mesenchymal, migratory,
and mammosphere-enriched phenotype, whereas the MECEPC+
cells exhibited epithelial traits and luminal differentiation.
Wnt and TGF-b Signals Govern Interconversions
between Basal and Luminal MECs
We investigated whether the autocrine loops operative in HTwist
and MSP cells were also active in MECEPC– populations. Indeed,we observed high mRNA levels of Axin2 (Figure S6G) as well as
cells with cytoplasmic/nuclear b-catenin and nuclear Smad2 in
the MECEPC– but not in the MECEPC+ cells (Figure 6E and
Figure S6H).
We then tested the effects of inhibiting autocrine signaling on
mammosphere formation and motility. Because recombinant
BMP4 exerted a strong antiproliferative effect on primary
MECs (data not shown), we inhibited TGF-b signaling in parallel
with two different TGFBRI kinase inhibitors and blocked auto-
crine Wnt signaling through application of recombinant SFRP1.
A 5 day pretreatment ofMECEPC– cells with the TGFBRI inhibitors
or with SFRP-1 reduced subsequent mammosphere formation
by 80%–90% (Figure 6F). Furthermore, we observed a complete
inhibition of motility by pre-treatment with the TGFBRI inhibitors
and a 3-fold reduction by SFRP1 (Figure 6G). Importantly, inhibi-
tion of these autocrine loops did not reduce the proliferation of
MECEPC– cells in monolayer cultures (Figure S6I).
When added at lower concentrations, TGFBRI inhibitors
added together with SFRP1 had a synergistic effect in suppress-
ingmammosphere formation (84% reduction jointly compared to
50% when each was added alone, Figure S7A). We also found
that a 5-day-long treatment with either TGFBRI inhibitor or
SFRP1 yielded increased tight and adherens junction formation
in MECEPC- (Figure S7C) and reduced the expression of Slug
and p63, as gauged by immunofluorescence and RT-PCR
(Figures S7B and S7C). Indeed, after combination treatment
of TGFBRI inhibitor together with SFPR1, transcript levels
of p63 and Slug were reduced to levels comparable to those in
MECEPC+ cells, whereas Claudin-2 mRNA, associated with the
epithelial state, was upregulated (Figure S7B), suggesting a
luminal differentiation process.
Analogous to our earlier experiments, we also determined
whether the EMT-IC could be applied toMECEPC+ cells to induce
migratory and mammosphere-forming abilities. We found that
a 5 day pretreatment of MECEPC+ cells with TGF-b, E-cadherin
antibody, or a combination of neutralizing DKK1 and SFRP1 anti-
bodies together with Wnt5a (functioning as activators of the
canonical and noncanonical Wnt pathways, respectively)
increased subsequent migration and mammosphere formation
3- to 5-fold. However, when added together, these factors did
not function in either an additive or synergistic manner (Figures
S7D and S7E).
We speculated that a sequential activation of Wnt and TGF-b
signaling might allow MECEPC+ cells to respond to both signals.
Indeed, a 3 day pretreatment with the Wnt activators prior to
addition of TGF-b, E-cadherin antibody, or a combination of
both for an additional 2 days resulted in a synergistic increase
of migration and mammosphere formation (Figures 7A and 7B).
Importantly, when primary mammospheres were dissociated
and placed into secondary sphere assays, we observed an
expansion of the proportion of sphere-forming cells only in
MECEPC+ cells that had been treated with all factors, reaching
a representation similar to that observed in MECEPC– cells
(Figure 7B).
Additionally, MECEPC+ cells exposed to all agents present in
the IC showed the greatest decrease in junctional E-cadherin,
b-catenin, and ZO-1 expression and greatest increase in Slug
and p63 expression (Figures 7C and 7D). By contrast, variousCell 145, 926–940, June 10, 2011 ª2011 Elsevier Inc. 935
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Figure 6. Characterization of Primary Mammary Epithelial Cell Populations Enriched in Self-Renewal and Motility
(A) Mammosphere assay: microscopy images of mammospheres and quantification of mammosphere formation by FACS-purified MECEPC– cells, MECEPC+
cells, and unsorted MECs (Figure S6A) after 5 days of monolayer culture. Primary spheres formed over a period of 7 days were dissociated and seeded for
secondary sphere formation. n = 48.
(B) Migration assay: microscopy images of migrated cells and quantification. n = 6 wells.
(C–E) Immunofluorescence: expression of mesenchymal and epithelial markers in MECEPC– and MECEPC+ cells after 5 days of monolayer culture. Vimentin, pan-
cytokeratin (panCK), E-cadherin, and ZO-1 (C), and EMT-TF Twist, Slug, and ZEB1 (D), and beta-catenin and Smad2 (E).
(F) Mammosphere assay: MECEPC– cells were seeded into assay after a 5 day pretreatment with TGFBRI inhibitors A83-01, SB435142 (SB43, both at 10 mM), and
recombinant SFRP1 (1 mg/ml). n = 24.
(G) Migration assay: MECEPC– cells were seeded into migration assays after 5 day pretreatment as described in (C). n = 6.
Data are presented as mean ± SEM. See also Figure S6.
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Figure 7. Wnt and TGF-b Signals Govern Conversions between Basal and Luminal MECs
(A) Mammosphere assay: FACS-purified MECEPC+ cells were cultured for 3 days in the presence of Wnt pathway-stimulating factors referred to as WNT
(anti-DKK1 antibody [10 mg/ml], anti-SFRP1 antibody [2 mg/ml], recombinant Wnt5a [250 ng/ml]), followed by 2 days in the additional presence of recombinant
TGF-b1 (0.1 ng/ml), anti-E-cadherin antibody (aEC, 2 mg/ml), or a combination of both. Secondary spheres were generated by dissociation of primary spheres.
*Primary versus secondary sphere forming cells, p < 0.0005. n = 10.
(B) Migration assay: before plating into Boyden chambers, MECEPC+ cells were treated as described in (A). n = 3.
(C) Immunofluorescence: MECEPC+ cells were treated as described in (A) and expanded for 2 days in the absence of further treatment. Expression of E-cadherin,
ZO-1, beta-catenin, Smad2, Slug, and p63.
(D) RT-PCR: mRNA expression of p63, Slug, Axin2, and E-cadherin in MECEPC+ cells after treatment as described in (A), followed by expansion for 2 days in the
absence of further treatment.
Data are presented as mean ± SEM. See also Figure S7.combinations of these factors led to partial EMT phenotypes
with mild disruption of adherens and tight-junction formation.
Importantly, the highest levels of nuclear Smad2 as well as cyto-plasmic and nuclear b-catenin and upregulation of Axin2 mRNA
were observed in MECEPC+ cells exposed to the IC, indicating
establishment of autocrine Wnt and TGF-b signaling (FiguresCell 145, 926–940, June 10, 2011 ª2011 Elsevier Inc. 937
7C and 7D). Together, these data demonstrated a remarkable
plasticity in MECEPC+ cells: exposure of these cells to DKK1-,
SFRP1-, and E-cadherin-neutralizing antibodies, together with
TGF-b and Wnt5a, resulted in the collaborative induction of
mesenchymal and basal traits, as well as motility and mammo-
sphere-forming ability.
DISCUSSION
An array of contextual signals has been implicated in the induc-
tion of an EMT, almost invariably in cells that have undergone
unknown predisposing genetic changes (Thiery et al., 2009).
Using primary normal, immortalized, and neoplastic human
MECs, we demonstrate that the EMT program cannot be effi-
ciently induced by activation of one or another signaling
pathway. Instead, multiple pathways must collaborate with one
another to do so.
The present data extend an experimental paradigm described
14 years ago, when it was shown that TGF-b is able to induce an
EMT in RAS-transformed mouse MECs (Oft et al., 1996). In our
hands, TGF-b signaling, while necessary, is not sufficient for
this conversion in human MECs and instead requires collabora-
tion of two Wnt signaling pathways. Our observations indicate
that some of the factors necessary for the induction of these
three EMT-inducing autocrine signaling loops are secreted by
cells that reside in an epithelial state. However, these factors
fail to establish autocrine signaling loops because of the
concomitant secretion of inhibitors. Accordingly, a permissive
environment for the induction of an EMT can be created by
reducing the levels of secreted inhibitors of these pathways,
specifically SFRP1, DKK1, and BMPs. Future studies are needed
to determine directly whether such a mechanism operates in
the intact mammary gland and, more generally, in the homeo-
stasis of other epithelial tissues. Thus, it remains to be demon-
strated that the signaling circuits critical to EMT induction in
human MECs operate as well in a variety of others epithelial
cell types.
Once cells have passed through an EMT, both normal and
neoplasticMECsmaintain their residence in the resultingmesen-
chymal/SC state by ongoing autocrine signaling, doing so
through the same signals that previously induced entrance into
this state. Thus, we observed that after a 14 day treatment
period, continued exposure to the EMT- IC was no longer
required. Our data suggest that this is due to the establishment
of a network of mutually reinforcing autocrine loops engaging
both Wnt and TGF-b pathways. These autocrine loops presum-
ably serve to ensure continued expression of the EMT transcrip-
tional circuitry. Indeed, during experimental induction of an EMT,
we observed activation of the expression of several EMT-
inducing TFs, notably Slug, Twist, ZEB1, and ZEB2. Further
support of this biological concept comes from the work of
others, demonstrating that embryonic (Ogawa et al., 2007),
muscle (Abou-Khalil et al., 2009), mesenchymal (Rider et al.,
2008), and neural (Toda et al., 2003) SCs secrete growth factors
in an autocrine manner to protect themselves from spontaneous
differentiation and to support their self-renewal.
Responding to these findings, we suggest that residence in
the mesenchymal/SC state can be destabilized if extracellular938 Cell 145, 926–940, June 10, 2011 ª2011 Elsevier Inc.autocrine loops are disrupted by exposure to their endogenous
inhibitors, i.e., the Wnt antagonists DKK1 and SFRP1, as well
as BMPs. Thus, in our own hands, disruption of autocrine
signaling leads to the reduction of migratory and mammo-
sphere-forming ability in immortalized MECs and to inhibition
of metastasis and tumor-initiating ability in their transformed
derivatives.
We find that the same set of signals that induce and maintain
mesenchymal/SC traits via induction of an EMT program in
immortalized and transformed HMLE cells also governs
interconversions between primary SC/progenitor cell-enriched
(basal) and lineage-restricted (luminal) MECs. These data
suggest that, given a permissive signaling context, a high degree
of plasticity exists within normal MEC populations and provide
direct support for the emerging notion that normal and
neoplastic epithelial cells utilize very similar SC programs.
A number of additional factors have been found capable of
inducing an EMT in a variety of epithelial cell types, including
Notch, Sonic Hedgehog, and various growth factors that acti-
vate tyrosine kinase receptors. We suggest that the physiologic
relevance of these factors and their roles in maintaining the
mesenchymal/SC state can be gauged by studying epithelial
cells of various tissue origins that undergo spontaneous
entrance into this state, such as the MSP cells we describe in
this manuscript. Such work may reveal alternative mechanisms
of stabilizing residence in the mesenchymal/SC state in other
epithelial tissues. It also remains possible that the pathways
described here represent core EMT-inducing signals shared in
common by a variety of epithelial cell types and that other docu-
mented EMT-inducing signaling pathways ultimately converge
on the three studied here.
In the longer term, the present observations may provide the
basis for efficiently inducing differentiated epithelial cells to
pass through an EMT and enter into a SC state without relying
on genetic alteration, such as introduction of genes specifying
EMT-TFs. Such an approach may eventually be of great utility
in the area of regenerative medicine in those instances where
the rapid regeneration of damaged epithelial tissues is required.
Acting in the opposing direction, the tumor-initiating cells of
certain carcinomas may be forced to exit the mesenchymal/SC
state by therapeutically interrupting multiple autocrine signaling
pathways required for their continued residence in this state.
EXPERIMENTAL PROCEDURES
Migration and Invasion Assays
Twenty-five thousand cells were seeded into 24-well cell culture inserts with
8 mm pores (BD Falcon). After 12–48 hr, the cells on the upper surface of the
filters were removed with a cotton swab. For visualization, cells on lower filter
surfaces were fixed and stained with a Diff-Quick staining kit (Dade Behring).
Three to five fields per filter were counted. Data are presented as migrated
cells per field.
Mammosphere and Tumorsphere Assay
Assays were performed as previously described with modifications (Dontu
et al., 2003): 1000 cells/well were seeded in 96-well ultra-low adhesion plates
(Corning) in MEGMmedium containing 1.3%methylcellulose (Stem Cell Tech-
nologies) supplemented with 20 ng/ml EGF, 10 ng/ml bFGF (Sigma), and B27
(GIBCO). For secondary sphere formation, primary spheres were dissociated
by trypsinization and replated at 1000 cells/well.
Animal Studies
Research involving animals complied with protocols approved by the MIT
Committee on Animal Care. For tumorigenicity studies, cells suspended in
100 ml Matrigel/PBS mix (BD Biosciences) were injected subcutaneously in
the flanks of age-matched nude (nu/nu) mice. Mice were sacrificed and nec-
ropsied after 10 weeks. For orthotopic injections, 1 3 105 cells suspended in
PBS were injected into the inguinal mammary glands of age-matched female
NOD/SCIDmice. Mice were sacrificed after 10 weeks or when tumors reached
a diameter >1 cm. For tail-vein injections, 13 105 cells suspended in PBSwere
injected into the tail vein of age-matched, male NOD/SCID mice. Lung surface
metastases were counted with a fluorescent microscope.
Immunoblots
Protein was extracted with RIPA lysis buffer. Protein lysates were resolved on
a 4%–12% Bis-Tris Gel, transferred to PVDF membranes, probed with HRP-
linked secondary antibodies (GE Healthcare), and visualized with ECL reagent
(Thermo Scientific).
Immunofluorescence
Cells were grown on Labtek II-CC2 Chamber slides (Nunc), fixed with 4%
paraformaldehyde, and permeabilized with 0.2% Triton X-100/PBS prior
blocking with 10% goat serum (Caltag). Secondary antibodies were goat-
anti-mouse or -rabbit coupled to Alexa-488 or -594 (Invitrogen). Cell nuclei
were visualized with DAPI (Sigma). Slides were mounted with SlowFade
Gold antifade reagent (Invitrogen).
Fluorescence-Activated Cell Sorting and Flow Cytometry
Cells were prepared according to standard protocols and suspended in 0.1%
BSA/PBS on ice prior to FACS. 7-AAD (BD Biosciences) was used to exclude
dead cells. Cells were sorted on a BD FACSAria SORP and analyzed on a BD
LSRII with BD FACSDiva Software (BD Biosciences).
RNA Preparation and RT-PCR Analysis
RNA was isolated with the RNeasy Micro kit (QIAGEN). Reverse transcription
was performed with the Superscript III First Strand Synthesis kit (Invitrogen).
SYBR Green Mix I (Roche Diagnostics) was used for amplification, and
samples were run on a Lightcycler-II Instrument (Roche Diagnostics). Analysis
was described previously (Yang et al., 2004). L32 was used as loading control
(n = 3). Primers are listed in Table S5.
Statistical Analysis
Data are presented as mean ± SEM. A Student’s t test (two-tailed) was used to
compare two groups (p < 0.05 was considered significant) unless otherwise
indicated.
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Microarray data have been deposited in the GEO archive under accession
number GSE28681.
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